Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Start Date
1/11/2023
Completion Date
9/1/2029
Summary
Data on valve performance following ViV-TAVR has usually been obtained with the use of Doppler-echocardiography. However, some reports have shown significant discordances in the evaluation of mean transvalvular gradient between echocardiography and catheterization, with an overestimation of the real gradient with echo (vs. cath) in most cases. Thus, the incidence of procedural-device failure may be lower than that reported in the ViV-TAVR literature,
Detailed Description
This is a prospective, multicenter, randomized, single-blinded design trial including patients with surgical aortic bioprosthetic dysfunction in the presence of a stented surgical bioprosthesis with a labeled size ≤25 mm. Following the Heart Team's decision to proceed with a ViV-TAVR procedure with the SAPIEN 3 ULTRA valve (or its subsequent iterations), patients will be randomized to valve hemodynamic optimization according to Doppler-echocardiography versus cardiac catheterization parameters.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Doppler-echocardiography
Invasive hemodynamic measurements
Conditions
Locations
University of California
San Francisco, California 94143
United States
South Broward Hospital Disctrict D/B/A Memorial Healthcare System
Hollywood, Florida 33021
United States
William Beaumont Hospital
Royal Oak, Michigan 48073
United States
Mayo Clinic
Rochester, Minnesota 55905
United States
St-Joseph's Health INC
Syracuse, New York 13203
United States
The Christ Hospital Health Network
Cincinnati, Ohio 45219
United States
IUCPQ
Québec, Quebec G1V 4G5
Canada